The FDA has approved the first generic versions of Novartis’ epilepsy treatment Trileptal (oxcarbazepine).

Roxane Laboratories, Sun Pharmaceuticals and Glenmark Pharmaceuticals won approval to sell versions of oxcarbazepine in three strengths – 150 mgs 300 mgs, and 600 mgs.

US sales of Trileptal were $549 million in 2006.